Although recent advances have been made in Arid1a related to embryonic development, tissue repair, cell aging, apoptosis, and tumor formation, it remains unclear whether manipulating Arid1a is sufficient to enable axon regeneration or increase RGC survival following optic nerve injury in vivo. This evidence concerns the gene ARID1A and neoplasm.